Development and specificity of endogeneous tumor-infiltrating regulatory T cells

描述（由申请人提供）：Foxp 3+调节性T细胞（“T细胞”）对于调节免疫稳态、器官特异性耐受和炎症至关重要。由于Treg在免疫调节中的核心作用，以及Treg在各种人类癌症中的普遍存在，许多新兴的治疗策略都集中在疫苗接种同时调节或耗尽Treg，以刺激有效的抗肿瘤免疫反应。然而，很少有人知道的发展起源，特异性和原位功能的肿瘤浸润性甲状腺肿。迄今为止，Foxp 3 + T细胞对肿瘤相关抗原反应的研究依赖于模型外源抗原在肿瘤细胞上的异位表达。然而，由于Treg识别的天然抗原是未知的，这些实验系统可能无法正确地概括Treg生物学的几个基本方面。因此，为了了解肿瘤相关Treg的真实性质，开发直接分析内源性抗原特异性Treg群体的新系统至关重要。在我们正在进行的工作中，我们已经确定了一个人口的自然发生的Foxp 3 + TCRs表达保守的TCR？？其在患有前列腺癌的小鼠中通过抗原驱动的选择而高度富集（在下文中，这种特异性的细胞将被称为“RT 3”T细胞），并产生表达这种RT 3“Treg TCR”的转基因小鼠。本提案的总体目标是了解内源性RT 3 Treg应答的发育、谱系可塑性和“特异性”。我们的中心假设是，RT 3 T细胞是在胸腺中发育的“天然”Foxp 3 + T细胞，并且这些T细胞对共同抗原和共同刺激物有反应，而这些共同抗原和共同刺激物对前列腺癌没有特异性。为了解决这一假设，我们将使用互补的方法：a）分析的发展，分化和纯化的TCR转基因细胞群转移到荷瘤宿主后的稳定性，和B）定量的典型的RT 3 TCR？使用“深度”TCR测序，对来自荷瘤小鼠的内源性T细胞亚群中的转录物进行分析。我们计划通过追求以下三个具体目标来测试我们的中心假设并实现本申请的目标。在目的1中，我们将检验如下假设：作为Foxp 3 + Treg分化成Foxp 3-细胞的结果，具有相同RT 3特异性的Foxp 3-neg效应T细胞和Foxp 3 + Treg在荷瘤小鼠中同时发育。在目的2中，我们将检验Foxp 3 + RT 3 TcR是在胸腺中发育的“天然”TcR群体，并且通过抗原驱动选择在前列腺肿瘤中高度富集的假设。最后，在目标3中，我们将检验RT 3 TcR不是前列腺癌特异性的，而是对共有抗原和共同刺激物有反应的假设。这些目标的完成将为调节性T细胞的生物学提供基本的见解，这将指导旨在通过选择性调节或耗尽肿瘤相关T细胞来诱导癌症消退的治疗策略的开发。

DESCRIPTION (provided by applicant): Foxp3+ regulatory T cels ("Tregs") are critical for the regulation of immune homeostasis, organ-specific tolerance, and inflammation. Because of the central role of Tregs in immune modulation, and the prevalence of Tregs in various human cancers, many emerging therapeutic strategies have focused on the modulation or depletion of Tregs concomitant with vaccine administration, in an effort to stimulate effective anti-tumor immune responses. However, little is known about the developmental origins, specificity, and in situ function of tumor-infiltrating Tregs. To date, studies of Foxp3+ Tregs reactive to tumor-associated antigens have relied on the ectopic expression of model foreign antigens on tumor cells. However, since the natural antigens recognized by Tregs are unknown, these experimental systems may not correctly recapitulate several fundamental aspects of Treg biology. Therefore, in order to understand the true nature of tumor-associated Tregs, it is paramount to develop novel systems by which to directly analyze endogenous, antigen-specific Treg populations. In our ongoing work, we have identified a population of naturally occurring Foxp3+ Tregs expressing a conserved TCR?? that is highly enriched by antigen-driven selection in mice with prostate cancer (hereafter, cells of this specificity will be referred to as "RT3" T cells), and generated transgenic mice expressing this RT3 "Treg TCR". The overall objective of this proposal is to understand the development, lineage plasticity, and "specificity" of the endogenous RT3 Treg response. It is our central hypothesis that RT3 T cells are "natural" Foxp3+ Tregs that develop in the thymus, and that these Tregs are responsive to shared antigens and common stimuli that are not specific to prostate cancer. To address this hypothesis, we will use complementary approaches: a) analysis of the development, differentiation, and stability of purified TCR transgenic cell populations following transfer into tumor-bearing hosts, and b) quantification of canonical RT3 TCR? transcripts in endogenous T cell subsets from tumor-bearing mice using "deep" TCR sequencing. We plan to test our central hypothesis and accomplish the objectives of this application by pursuing the following three specific aims. In Aim 1, we will test the hypothesis that Foxp3neg effector T cells and Foxp3+ Tregs of the same RT3 specificity develop concurrently in tumor-bearing mice, as a result of Foxp3+ Treg differentiation into Foxp3neg cells. In Aim 2, we will test the hypothesis that Foxp3+ RT3 Tregs are a population of "natural" Tregs that develop in the thymus, and are highly enriched in prostate tumors by antigen-driven selection. Finally, in Aim 3, we will test the hypothesis that RT3 Tregs are not prostate cancer-specific, but are instead responsive to shared antigens and common stimuli. Completion of these aims will provide fundamental insight into the biology of regulatory T cells, which will guide the development of therapeutic strategies aimed at the induction of cancer regression through the selective modulation or depletion of tumor-associated Tregs.